Low-Dose Taxotere® (Docetaxel) With Concurrent Radiotherapy For Localized, Inoperable Carcinoma Of The Uterine Cervix

Inclusion Criteria: * Histologic confirmation of squamous, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix including FIGO (International Federation of Gynecologists and Obstetricians) stage IB to IVA with or without pelvic adenopathy. * No evidence of para-aortic or distant metastases. Must have evaluable disease. * Zubrod Performance Status 0-2 or Karnofsky Performance Status \> 60 * Laboratory values must be as follows: White blood cell count: \> 3,000/mm3,Absolute granulocyte count: \> 1,500/mm3, Hemoglobin \> 8.0 g/dl, Platelets: \> 100,000/mm3, Serum creatinine: \< 2.5 mg/dl, Serum calcium: \< 1.3 x institutional upper normal limit,Hepatic criteria as follows: Total Bilirubin \< ULN for the institution, * Signed study-specific informed consent p * Age \> 18 years. * Peripheral neuropathy must be \< grade 1. Exclusion Criteria: * Prior or simultaneous malignancies (other than skin cancer) unless disease-free * Medical illness preventing the use of taxane-based chemotherapy. * Carcinoma of the cervix with the following histology: melanoma, sarcoma, small carcinoid, glassy cell, clear cell, and adenoid cystic. * Previous or current medical or psychiatric illness that would prevent informed consent * Patients known to be infected with HIV or a history of AIDS are excluded. * Prior surgery for carcinoma of the cervix other than a biopsy. * Patients with para-aortic disease. * Previous pelvic radiation therapy or systemic chemotherapy is not permitted. * Women who are pregnant or breast-feeding are excluded from this study. * Previous history of hypersensitivity reaction to Taxotere or other drugs formulated with polysorbate 80 must be excluded.